Valeant to Discuss Philidor Transition in Call With InvestorsBy
Valeant Pharmaceuticals International Inc. will discuss its transition away from controversial pharmacy partner Philidor Rx Services LLC and provide an update on the company’s operations on a conference call Tuesday.
Chief Executive Officer Michael Pearson will host the call, along with Chief Financial Officer Robert Rosiello, Company Group Chairmen Ari Kellen and Deb Jorn, and Corporate Controller Tanya Carro, according to a statement Monday.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.